Why patient care is a public affair

The VP of public affairs at Kyowa Kirin discusses her role in advocating for advocacy.

By Taren Grom • Feb. 23, 2023

Woman of the Week: Alltrna’s Michelle Werner

The first-time CEO has her sights on addressing thousands of diseases with the company’s tRNA platform.

By Taren Grom • Feb. 22, 2023

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

Tapping into the molecular fountain of youth

Kristen Fortney, CEO of BioAge Labs, wants to improve the human life span by focusing on the human health span.

By Alexandra Pecci • Feb. 22, 2023

Pheast’s new CEO on how its ‘don’t eat me’ platform could deliver next-gen precision immunotherapies

Jacopo Leonardi’s latest venture is in the burgeoning field of macrophage inhibitors that could target a wide range of cancers.

By Taren Grom • Feb. 17, 2023

Nectin’s Keytruda combo could fill gaps in immuno-oncology’s treatment paradigm

The Israeli biotech just entered into a collaboration with Merck to develop its own checkpoint inhibitor alongside the bestselling cancer treatment.

By Michael Gibney • Feb. 16, 2023

Woman of the Week: Bristol Myers Squibb’s Ester Banque

The 30-year veteran is heading up the “transformation” of one of the pharma giant’s most important therapeutic portfolios: hematology.

By Taren Grom • Feb. 15, 2023

Managing for resilience: Passage’s ups and downs in gene therapy

After a rocky year, Passage Bio’s CEO is focused on helping the rare disease specialist bounce back.

By Meagan Parrish • Feb. 15, 2023

Brian Fox is bringing ‘fresh eyes’ to ad agency Klick

Why the recently appointed president of commercial solutions sees near limitless potential to expand Klick’s footprint across the life sciences — and how generative AI is playing a role.

By Karissa Waddick • Feb. 13, 2023

Bayer, Astellas switch CEOs amid major inflection points

Bayer’s Bill Anderson and Astellas’ Naoki Okamura will be charged with setting the companies on growth trajectories for 2023.

By Karissa Waddick • Feb. 9, 2023

The unique playbook of Biohaven’s CEO

Vlad Coric’s offbeat business strategy paid off once with a Pfizer buyout. Can he do it again?

By Meagan Parrish • Feb. 8, 2023

Woman of the Week: KaliVir Immunotherapeutics’ Helena Chaye

The triple threat CEO — scientist, lawyer and biotech pro — thinks she’s discovered a key to curing a wide range of cancers.

By Taren Grom • Feb. 8, 2023

Roche, Chiesi and the FDA change major leadership roles as they strive for growth in 2023

From Roche’s new pharma chief to the departure of the FDA’s gene therapy head, these moves are bound to shake up the industry.

By Karissa Waddick • Feb. 6, 2023

Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement

Victoria Richon’s latest venture is in the burgeoning field of protein-enhancing drugs that could target a range of diseases.

By Kelly Bilodeau • Feb. 6, 2023

Execs at Pfizer, Novartis, Amgen and GSK tackle shifting priorities — reflecting the state of Big Pharma

A menagerie of earnings calls this week showed where the Big Pharma players stand in 2023.

By Michael Gibney • Feb. 2, 2023

Woman of the Week: Bayer’s Dr. Yesmean Wahdan

The VP of medical affairs and women’s health is focused on an audacious goal to meet the needs of 100 million women globally.

By Taren Grom • Feb. 1, 2023

This biotech CEO secured two billion-dollar Big Pharma deals during the pandemic

With the industry focused on cancer and COVID-19, Marc de Garidel made deals centered on cardio.

By Michael Gibney • Jan. 31, 2023

Gilead’s commercial chief on why 2023 will be a ‘coming out’ year

With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.

By Meagan Parrish • Jan. 26, 2023

Economic crisis? J&J execs say that won’t stop them from hitting $60B target

The pharma giant's CEO Joaquin Duato and CFO Joseph Wolk showed that they're optimistic about reaching lofty goals despite hard economic times.

By Michael Gibney • Jan. 25, 2023

Woman of the Week: Dr. Lauren Lazar

As Calcium’s medical director, Lazar is leveraging next-generation innovation to create strategic connections between science and marketing for healthcare brands.

By Taren Grom • Jan. 25, 2023

Woman of the Week: Genetika+’s Talia Cohen Solal

The CEO is aiming to build a “brain-in-a-dish” to treat all patients for better mental health outcomes.

By Taren Grom • Jan. 18, 2023

Biopharma M&A may get the push it needs in 2023, but with a face lift

A flurry of recent deals has reinforced forecasts that the long drought is over — circumstances have changed though, and M&A may not be the same.

By Michael Gibney • Jan. 12, 2023

C-suite changes at Biogen, Bluebird, Novavax give insight into 2023 business plans

A breakdown of the most buzzworthy executive changes so far in the new year and how they’re causing ripples in the life sciences industry.

By Karissa Waddick • Jan. 10, 2023

Chinook Therapeutics nears the finish line in kidney disease

A company focused on kidney disease, Chinook is growing into a commercial outfit as its lead candidate approaches the market.

By Michael Gibney • Jan. 10, 2023

The kindred nature of martial arts and drug development

How the IRLAB Therapeutics CEO is guiding the company in its development of potentially groundbreaking Parkinson’s disease treatments.

By Alexandra Pecci • Jan. 9, 2023

What’s top of mind for industry execs at JPM?

Leaders in the space reveal the topics that are top of mind as the year’s biggest healthcare conference kicks off next week.

By Taren Grom • Jan. 6, 2023